Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00297505 |
The purpose of this study is to compare the effects of citalopram versus placebo given in the context of contingency management for cocaine dependence.
Condition | Intervention | Phase |
---|---|---|
Cocaine Dependence |
Drug: citalopram |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Serotonin, Impulsivity, and Cocaine Dependence Treatment |
Estimated Enrollment: | 120 |
Study Start Date: | April 2001 |
Estimated Study Completion Date: | November 2004 |
Cocaine dependence continues to be a significant public health problem, for which there is no FDA approved pharmacotherapy. This study is a 12-week, double blind, placebo controlled trial of citalopram for cocaine dependence. The primary outcome measure is benzoylecgonine positive urines. Secondary measures of side effects and craving are also examined.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
University of Texas – Houston Health Science Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Frederick G Moeller, M.D. | The University of Texas Health Science Center, Houston |
Study ID Numbers: | R01-DA08425 |
Study First Received: | February 27, 2006 |
Last Updated: | February 27, 2006 |
ClinicalTrials.gov Identifier: | NCT00297505 History of Changes |
Health Authority: | United States: Federal Government |
Cocaine; citalopram; impulsivity; serotonin |
Dopamine Uptake Inhibitors Neurotransmitter Agents Cholinergic Antagonists Psychotropic Drugs Disorders of Environmental Origin Anesthetics Cholinergic Agents Dopamine Mental Disorders Substance-Related Disorders Vasoconstrictor Agents Antidepressive Agents, Second-Generation Cocaine |
Dexetimide Antidepressive Agents Cocaine-Related Disorders Central Nervous System Depressants Cardiovascular Agents Serotonin Uptake Inhibitors Citalopram Serotonin Anesthetics, Local Muscarinic Antagonists Dopamine Agents Peripheral Nervous System Agents |
Dopamine Uptake Inhibitors Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Anesthetics Disorders of Environmental Origin Antiparkinson Agents Cholinergic Agents Sensory System Agents Mental Disorders |
Therapeutic Uses Vasoconstrictor Agents Substance-Related Disorders Antidepressive Agents, Second-Generation Cocaine Dexetimide Antidepressive Agents Cocaine-Related Disorders Central Nervous System Depressants Cardiovascular Agents Citalopram Serotonin Uptake Inhibitors Anesthetics, Local Serotonin Pharmacologic Actions |